The Vitamin Shoppe (VSI) Earning Favorable Media Coverage, Study Shows

The Vitamin Shoppe (VSI) Earning Favorable Media Coverage, Study Shows

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

News stories about Vitamin Shoppe (NYSE:VSI) have been trending positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vitamin Shoppe earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the specialty retailer an impact score of 46.1018075635502 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Vitamin Shoppe (NYSE VSI) traded down 2.36% during midday trading on Wednesday, reaching $10.35. The company’s stock had a trading volume of 129,295 shares. The firm has a 50 day moving average price of $11.06 and a 200 day moving average price of $16.58. Vitamin Shoppe has a 1-year low of $9.80 and a 1-year high of $28.94. The firm has a market capitalization of $239.74 million, a PE ratio of 13.32 and a beta of 0.68.

Vitamin Shoppe (NYSE:VSI) last posted its quarterly earnings data on Wednesday, May 10th. The specialty retailer reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.58 by $0.21. The business had revenue of $316.90 million during the quarter, compared to analyst estimates of $325.71 million. Vitamin Shoppe had a return on equity of 9.35% and a net margin of 1.43%. Vitamin Shoppe’s revenue for the quarter was down 5.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. On average, analysts predict that Vitamin Shoppe will post $1.57 EPS for the current year.

VSI has been the topic of several research analyst reports. Barclays PLC restated an “equal weight” rating and set a $13.00 price objective (down from $24.00) on shares of Vitamin Shoppe in a research note on Sunday, May 14th. BidaskClub cut Vitamin Shoppe from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. ValuEngine cut Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Gabelli cut Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, Zacks Investment Research cut Vitamin Shoppe from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 13th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $24.00.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Related posts

Leave a Comment